FILTER
FILTERED INTERVIEW RESULTS
Kendalle O’Connell
CEO AND PRESIDENT, MASSBIO
"In 2022, Massachusetts received 25% of all biopharma VC funding in the US. We are seeing new clusters emerge outside the traditional hubs of Kendall Square and Boston."
Arda Ural
AMERICAS INDUSTRY MARKET LEADER, HEALTH SCIENCES & WELLNESS, EY USA
"We are going to help the industry digitalize, prepare for the innovation deficit due to expiring patents and improve strategies that lead to better M&A opportunities."
David Schaffer
EXECUTIVE DIRECTOR, QB3
"The Bay Area offers a confluence of universities, investors and companies, and we are interested in strengthening bridges between these institutions to streamline the process of technology translation."
Mark A. Goldberg
CEO, ALLUCENT
"Given that a significant amount of intellectual property and cutting-edge science resides within smaller companies, we created a purpose-built firm to help smaller players develop their products and bring them to market."
Gil Roth
PRESIDENT, PBOA
"The Ukraine crisis highlighted how Europe needs to look at its energy supply and how it will make sure they have secure supply chains. Part of that has involved the US more closely. Geopolitics will have a more significant impact going forward."
Terry Myerson
CEO, TRUVETA
"Truveta Studio is the first data and analytics solution to study patient care and outcomes for all conditions, drugs, and medical devices. Pfizer is using Truveta Studio to study COVID-19."
Ajay Tandon
MANAGING DIRECTOR, VEEDA CLINICAL RESEARCH
"We now offer end-to-end modular technical services, encompassing both pre-clinical and clinical development of biosimilars addressing global regulatory requirements."
Gaurav Kaushik
MANAGING DIRECTOR AND CEO, METEORIC BIOPHARMACEUTICALS
"We are looking into new ways to reap the benefits of artificial intelligence, particularly on the clinical side. On the physical side, Meteoric Biopharmaceuticals will have a new factory and lab up and running by the end of 2024, that will work on advanced fermentation processes."
Liping Liu
FOUNDER & CEO, HIGHTIDE THERAPEUTICS
"As more robust drug candidates are emerging, I am willing to bet that we will have the first NASH drug approved in 2023."
Anwar Daud
MANAGING DIRECTOR, ZIM LABORATORIES
"ZIM sees great opportunity in improving the functioning of the overall healthcare system through providing more patient centric drug delivery systems."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Latin America Petrochemicals and Chemicals 2024 - Digital Interactive
The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.
The Latin America Petrochemicals and Chemicals 2024 report, produced in alliance with APLA, explores the current state of these industries, the challenges they face, and the opportunities they offer.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
